Arcturus Therapeutics Holdings Inc.

NasdaqGM:ARCT Stock Report

Mkt Cap: US$503.8m

We’ve recently updated our valuation analysis.

Arcturus Therapeutics Holdings Valuation

Is ARCT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ARCT?

Other financial metrics that can be useful for relative valuation.

ARCT key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue7x
Enterprise Value/EBITDA-2.5x
PEG Ration/a

Price to Sales Ratio vs Peers

How does ARCT's PS Ratio compare to its peers?

The above table shows the PS ratio for ARCT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average11.7x
SRNE Sorrento Therapeutics
9.2x45.5%US$552.5m
NRIX Nurix Therapeutics
14.7x45.8%US$575.2m
CCCC C4 Therapeutics
7.6x61.3%US$368.6m
SRRK Scholar Rock Holding
15.4x52.7%US$572.4m
ARCT Arcturus Therapeutics Holdings
9.8x40.1%US$503.8m

Price-To-Sales vs Peers: ARCT is good value based on its Price-To-Sales Ratio (9.8x) compared to the peer average (11.7x).


Price to Earnings Ratio vs Industry

How does ARCT's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a13.9%
n/an/an/a

Price-To-Sales vs Industry: ARCT is good value based on its Price-To-Sales Ratio (9.8x) compared to the US Biotechs industry average (12.9x)


Price to Sales Ratio vs Fair Ratio

What is ARCT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ARCT PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio9.8x
Fair PS Ratio13x

Price-To-Sales vs Fair Ratio: ARCT is good value based on its Price-To-Sales Ratio (9.8x) compared to the estimated Fair Price-To-Sales Ratio (13x).


Share Price vs Fair Value

What is the Fair Price of ARCT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ARCT's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ARCT's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ARCT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$18.97
US$44.00
+131.9%
81.6%US$140.00US$14.00n/a10
Jan ’24US$16.96
US$44.00
+159.4%
81.6%US$140.00US$14.00n/a10
Dec ’23US$18.39
US$44.00
+139.3%
81.6%US$140.00US$14.00n/a10
Nov ’23US$18.28
US$45.10
+146.7%
86.7%US$140.00US$8.00n/a10
Oct ’23US$14.82
US$49.91
+236.8%
80.7%US$140.00US$8.00n/a11
Sep ’23US$15.43
US$49.91
+223.5%
80.7%US$140.00US$8.00n/a11
Aug ’23US$17.47
US$51.27
+193.5%
79.2%US$140.00US$8.00n/a11
Jul ’23US$16.16
US$55.55
+243.7%
74.8%US$140.00US$8.00n/a11
Jun ’23US$18.39
US$55.55
+202.0%
74.8%US$140.00US$8.00n/a11
May ’23US$19.38
US$63.45
+227.4%
63.9%US$140.00US$16.00n/a11
Apr ’23US$28.91
US$68.64
+137.4%
57.5%US$140.00US$16.00n/a11
Mar ’23US$22.08
US$71.36
+223.2%
58.2%US$140.00US$16.00n/a11
Feb ’23US$26.56
US$83.45
+214.2%
52.5%US$152.00US$30.00n/a11
Jan ’23US$37.01
US$85.45
+130.9%
50.0%US$152.00US$30.00US$16.9611
Dec ’22US$37.47
US$85.45
+128.1%
50.0%US$152.00US$30.00US$18.3911
Nov ’22US$47.13
US$78.46
+66.5%
53.6%US$152.00US$27.00US$18.2813
Oct ’22US$44.42
US$78.46
+76.6%
53.6%US$152.00US$27.00US$14.8213
Sep ’22US$56.40
US$78.46
+39.1%
53.6%US$152.00US$27.00US$15.4313
Aug ’22US$31.31
US$80.36
+156.7%
59.4%US$160.00US$23.00US$17.4714
Jul ’22US$35.94
US$81.08
+125.6%
61.0%US$160.00US$23.00US$16.1613
Jun ’22US$29.94
US$89.25
+198.1%
51.3%US$160.00US$23.00US$18.3912
May ’22US$36.66
US$91.50
+149.6%
47.2%US$160.00US$35.00US$19.3812
Apr ’22US$40.50
US$91.50
+125.9%
47.2%US$160.00US$35.00US$28.9112
Mar ’22US$54.64
US$92.31
+68.9%
39.4%US$152.00US$45.00US$22.0813
Feb ’22US$80.42
US$94.77
+17.8%
36.0%US$152.00US$46.00US$26.5613
Jan ’22US$43.38
US$100.18
+130.9%
37.3%US$152.00US$46.00US$37.0111

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies